利索-全球专利检索

  1. 登录
  2. 注册
发明授权
US07635690B2 HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine 失效
由β-2'，3'-二脱氢-2'，3'-二脱氧-5-氟胞苷选择的HIV-1突变

HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
摘要：
The present invention discloses a method for treating HIV that includes administering β-D-D4FC or its pharmaceutically acceptable salt or prodrug to a human in need of therapy in combination or alternation with a drug that induces a mutation in HIV-1 at a location other than the 70(K to N), 90 or the 172 codons of the reverse transcriptase region. Also disclosed is a method for using β-D-D4FC as “salvage therapy” to patients which exhibit drug resistance to other anti-HIV agents. β-D-D4FC can be used generally as salvage therapy for any patient which exhibits resistance to a drug that induces a mutation at other than the 70(K to N), 90 or the 172 codons.
摘要（中）：

本发明公开了一种治疗艾滋病毒的方法，其包括向需要治疗的人组合或交替给予β-D-D4FC或其药学上可接受的盐或前药，所述药物在其它位置诱导HIV-1中的突变 比70（K至N），90或反转录酶区域的172个密码子。 还公开了将β-D-D4FC用作对其他抗HIV药物具有耐药性的患者的“补救疗法”的方法。 一般来说，β-D-D4FC可用于任何对在70（K至N），90或172个密码子以外诱导突变的药物具有抗性的患者的补救疗法。

公开/授权文献
信息查询
Espacenet
0/0